Abbott Laboratories vs. Bolt Biotherapeutics, Inc. Common Stock
Abbott Laboratories (ABT) comes out ahead, leading on 6 of 8 compared factors.
Size & Scale
| ABT | BOLT | |
|---|---|---|
| Market Cap | $177.55 billion | $6.86 million |
| Revenue (TTM) | $46.59 billion | $4.70 million |
| Net Income (TTM) | $5.42 billion | $-28,739,000 |
ABT leads on 3 of 3 size & scale factors.
Valuation
| ABT | BOLT | |
|---|---|---|
| P/E Ratio | 33.21 | — |
| Price / Book | 3.43 | 0.54 |
| Price / Sales | 3.81 | 1.46 |
BOLT leads on 2 of 2 valuation factors.
Profitability
| ABT | BOLT | |
|---|---|---|
| Net Margin | 11.65% | -611.47% |
| Return on Equity | 10.48% | -227.37% |
ABT leads on 2 of 2 profitability factors.
Dividend
| ABT | BOLT | |
|---|---|---|
| Dividend Yield | 2.46% | — |
| Payout Ratio | 81.55 | — |
ABT and BOLT split the dividend factors evenly.
Risk & Sentiment
| ABT | BOLT | |
|---|---|---|
| Short Interest | 0.57% | 22.62% |
ABT leads on 1 of 1 risk & sentiment factors.
Dig deeper: ABT overview, ABT financials, BOLT overview, BOLT financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.